Destination Wealth Management Maintains Holdings in OncoCyte Corp (OCX)

Destination Wealth Management continued to hold its position in shares of OncoCyte Corp (NYSE:OCX) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 29,656 shares of the company’s stock at the end of the second quarter. Destination Wealth Management owned 0.10% of OncoCyte Corp worth $154,000 as of its most recent filing with the Securities & Exchange Commission.

TRADEMARK VIOLATION WARNING: “Destination Wealth Management Maintains Holdings in OncoCyte Corp (OCX)” was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this piece of content can be viewed at

OCX has been the subject of several research analyst reports. Zacks Investment Research raised OncoCyte Corp from a “sell” rating to a “hold” rating in a research note on Wednesday, July 19th. Chardan Capital reaffirmed a “buy” rating and issued a $7.75 price objective (up from $6.50) on shares of OncoCyte Corp in a research note on Tuesday, May 23rd.

OncoCyte Corp (NYSE:OCX) traded up 0.85% during trading on Friday, reaching $5.95. The company had a trading volume of 10,364 shares. OncoCyte Corp has a 52-week low of $3.75 and a 52-week high of $7.95. The firm’s market capitalization is $186.45 million. The company has a 50-day moving average of $6.04 and a 200-day moving average of $5.88.

OncoCyte Corp (NYSE:OCX) last released its earnings results on Monday, August 14th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). Analysts expect that OncoCyte Corp will post ($0.54) EPS for the current fiscal year.

About OncoCyte Corp

OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment.

Want to see what other hedge funds are holding OCX? Visit to get the latest 13F filings and insider trades for OncoCyte Corp (NYSE:OCX).

Institutional Ownership by Quarter for OncoCyte Corp (NYSE:OCX)

Receive News & Ratings for OncoCyte Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte Corp and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply